Image de couverture de livre

Steatotic Liver Disease Prevalence in China: A Population‐Based Study and Meta‐Analysis of 17.4 Million Individuals

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Zhenqiu Liu, Jiayi Huang, Luojia Dai, Huangbo Yuan, Yanfeng Jiang, Chen Suo, Li Jin, Tiejun Zhang, Xingdong Chen
Format:	Artículo Open Access
Publié:	Wiley 2025
Sujets:	Alimentary Pharmacology & Therapeutics
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Meta‐Analysis: Global Prevalence and Mortality of Cirrhosis in Metabolic Dysfunction‐Associated Steatotic Liver Disease
par: Soroor Owrangi, et autres
Publié: (2024)

Anthropometric Measures and Mortality Risk in Individuals With Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD): A Population‐Based Cohort Study
par: Yee Hui Yeo, et autres
Publié: (2025)

Prevalence and Predictors of Suspected Metabolic Dysfunction‐Associated Steatotic Liver Disease in Adolescents in the United States
par: Sheila L. Noon, et autres
Publié: (2025)

Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol
par: Karen Cheuk‐Ying Ho, et autres
Publié: (2025)

Editorial: Liver and Non‐Liver Outcomes Between Different Subtypes of Steatotic Liver Disease
par: Jee‐Fu Huang, et autres
Publié: (2026)

Editorial: Evaluating the Prevalence of Metabolic Dysfunction‐Associated Steatotic Liver Disease in Patients With Type 2 Diabetes and Hyperferritinaemia—Authors' Reply
par: Maral Amangurbanova, et autres
Publié: (2024)

Editorial: Prevalence of Suspected Metabolic Dysfunction‐Associated Steatotic Liver Disease in Adolescents in the United States Using Updated Diagnostic Criteria
par: Julie Bonn, et autres
Publié: (2025)

Editorial: Time to Genotype—Genetic Risk and Prognosis in Steatotic Liver Disease
par: Rosellina M. Mancina, et autres
Publié: (2025)

Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol—Authors' Reply
par: Federica Tavaglione, et autres
Publié: (2025)

Alcohol–Related Liver Disease, Followed by Metabolic Dysfunction–Associated Steatotic Liver Disease, Emerges as the Fastest‐Growing Aetiologies for Primary Liver Cancer in the United States
par: Pojsakorn Danpanichkul, et autres
Publié: (2025)

Editorial: Steatotic Liver Diseases Emerge as Rapidly Growing Drivers of Primary Liver Cancer in the United States
par: Kelly Torosian, et autres
Publié: (2025)

Gastrointestinal Cancer Risk in Steatotic Liver Diseases: MASLD , MetALD and ALD
par: Nobuharu Tamaki, et autres
Publié: (2025)

Waitlist and Post‐Transplant Outcomes in Liver Transplantation for Alcohol‐Associated Liver Disease: An Individual Patient Data Meta‐Analysis
par: Glenn Jun Kit Ho, et autres
Publié: (2025)

Letter: Combination Therapies With Vitamin E for Metabolic Dysfunction‐Associated Steatotic Liver Disease
par: Stergios A. Polyzos, et autres
Publié: (2024)

Editorial: Two Common Risks, One Greater Harm—Diabetes and Alcohol in Steatotic Liver Disease
par: Stine Johansen, et autres
Publié: (2026)

Subtype Differences in Major Adverse Liver Outcomes and Cardiovascular Events and Mortality in Steatotic Liver Disease: A UK Biobank Analysis
par: Takao Miwa, et autres
Publié: (2026)

Letter: Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease‐Related Liver Cancer—Results From the Global Burden of Disease Study 2021
par: Chunlong Liu, et autres
Publié: (2025)

Letter: Liver Transplantation Outcomes for Alcohol‐Associated Liver Disease—Commentary on an Individual Patient Data Meta‐Analysis and Future Research Directions
par: Xinglin Li, et autres
Publié: (2026)

Letter: Meta‐Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Disease
par: Cong Dai, et autres
Publié: (2024)

Letter on ‘Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD )’; Authors’ reply
par: Kaleb Tesfai, et autres
Publié: (2026)

Social Determinants of Health in Metabolic Dysfunction‐Associated Steatotic Liver Disease and All‐Cause/Cause‐Specific Mortality
par: Donghee Kim, et autres
Publié: (2025)

Letter: Liver Transplantation Outcomes for Alcohol‐Associated Liver Disease—Commentary on an Individual Patient Data Meta‐Analysis and Future Research Directions. Authors' Reply
par: Ryan Yanzhe Lim, et autres
Publié: (2026)

Association of High‐Sensitivity Troponins in Metabolic Dysfunction‐Associated Steatotic Liver Disease With All‐Cause and Cause‐Specific Mortality
par: Donghee Kim, et autres
Publié: (2025)

Predicting Hepatic Decompensation in Patients With Metabolic Dysfunction Associated Steatotic Liver Disease‐Related Cirrhosis: The ABID‐LSM Model
par: Luis Calzadilla Bertot, et autres
Publié: (2025)

Editorial: Does Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ) With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease?
par: C. C. Mark Cheah, et autres
Publié: (2025)

Advanced Fibrosis and Cardiometabolic Risk Burden Increase Major Cardiovascular Events in Chronic Hepatitis C Patients With Steatotic Liver Disease After Viral Eradication
par: Pei‐Chien Tsai, et autres
Publié: (2025)

Editorial: Does Metabolic Dysfunction‐Associated Steatotic Liver Disease With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease? Authors' Reply
par: Xiao‐Dong Zhou, et autres
Publié: (2025)

Extracellular Vesicles miRNome Profiling Reveals miRNAs Engagement in Dysfunctional Lipid Metabolism, Chronic Inflammation and Liver Damage in Subjects With Metabolic Dysfunction‐Associated Steatotic Liver Disease
par: Gian Paolo Caviglia, et autres
Publié: (2025)

Meta‐Analysis: Prevalence of Eating Disorders in Inflammatory Bowel Disease
par: Quinn Goddard, et autres
Publié: (2025)

Editorial: Comparable Hepatic Fibrosis Risk Demands Equal Vigilance in Lean and Non‐Lean Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease
par: Shinya Yokoyama, et autres
Publié: (2025)

Letter: Comparison of the Efficacy of Adjuvant PD‐1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) Related HCC Versus Other Aetiologies
par: Jia‐Yong Su, et autres
Publié: (2025)

Editorial: Comparable Hepatic Fibrosis Risk Demands Equal Vigilance in Lean and Non‐Lean Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease—Authors' Reply
par: Kaleb Tesfai, et autres
Publié: (2025)

Letter: Comparing the Efficacy of Adjuvant PD–1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease Related HCC Versus Other Aetiologies—Authors' Reply
par: Isabella Lurje, et autres
Publié: (2025)

Letter: Meta‐Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Disease—Authors' Reply
par: Isabel Carbery, et autres
Publié: (2024)

Diagnostic Impact of Liver Biopsy Among Antinuclear Antibody Positive Individuals With Mild Liver Enzyme Elevation
par: David Mehdi Asgher Niazi, et autres
Publié: (2026)

Editorial: Prevalence of Suspected Metabolic Dysfunction‐Associated Liver Disease in Adolescents in the United States Using Updated Diagnostic Criteria—Authors' Reply
par: Sheila L. Noon, et autres
Publié: (2025)

Pain and Sedative Medication Use Among Individuals With Inflammatory Bowel Disease: A Nationwide Population‐Based Cohort Study
par: Samantha Baillie, et autres
Publié: (2025)

Letter: Post‐HCV Cure, Precision Assessment of Liver Stiffness and Diabetes Risk in Maternal Populations—A Critical Research Need
par: Zihe Guan, et autres
Publié: (2025)

Factors Associated With Motivation to Reduce Alcohol Use Among Patients With Chronic Liver Disease
par: Derek D. Satre, et autres
Publié: (2024)

Meta‐Analysis: Prevalence and Incidence of Gastroparesis Following Lung or Heart Transplantation
par: Mohamed H. Eldesouki, et autres
Publié: (2026)